
    
      The purpose of this study is to establish the safety profile and the maximum tolerated dose
      (MTD) of the anti-VEGFR-2 monoclonal antibody IMC-1121B administered weekly in patients with
      advanced solid tumors who have not responded to standard therapy or for whom no standard
      therapy is available.
    
  